NCT05169307 - CPX-351 Real-World Effectiveness and Safety Study | Biotech Hunter

Enrollment

147

Participants

Timeline

Start Date

January 14, 2022

Primary Completion Date

June 15, 2022

Study Completion Date

June 15, 2022

Conditions

Acute Myeloid Leukemia

Interventions

DRUG

CPX-351

This is a retrospective, non-interventional, observational study. No study drug will be administered in this study.

Trial Locations (15)

Belfast City Hospital, Belfast

Bristol Royal Infirmary, Bristol

University Hospitals Derby and Burton, Derby

Western General Hospital (Lothian), Edinburgh

Royal Devon and Exeter, Exeter

The Leeds Teaching Hospitals NHS Trust, Leeds

Leicester Royal Infirmary, Leicester

University College London Hospitals, London

Royal Marsden, London

Royal Liverpool/Clatterbridge, Metropolitan Borough of Wirral

James Cook University Hospital, Middlesbrough

Peterborough Hospital, Peterborough

Queen Alexandra Hospital, Portsmouth, Portsmouth

Torbay and South Devon, Torquay

New Cross Hospital - Wolverhampton, Wolverhampton